Search
Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.
News
18 April 2024
While economic factors, including the high cost of capital, continue to keep our clients up at night, we also see signs of optimism in 2024. Against this fiscal backdrop, significant recent ...
News
02 April 2024
The Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and...
News
18 March 2024
The Federal Communications Commission (FCC) unanimously approved a Report and Order (R&O) creating a new voluntary Cybersecurity Labeling Program for Internet of Things (IoT) products....
News
21 February 2024
Speaking at the J.P. Morgan Healthcare Conference this year, Hogan Lovells life sciences regulatory partners Lowell Zeta and Blake Wilson, were joined by Greenleaf Health’s Kalah...
News
15 February 2024
The BIOSECURE Act (the “Act”), introduced by members of the House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party...
News
14 February 2024
In the latest edition of our False Claims Act Guide: 2023 and the road ahead, we analyze the key developments from 2023 and discuss how the most important cases and issues are shaping FCA...
Insights and Analysis
13 February 2024
The "new normal" of global data protection regulation is becoming increasingly complex. With 37 African countries having a comprehensive data protection legal framework and the...
News
06 February 2024
The U.S. Food and Drug Administration (FDA) published its long-awaited final rule to amend the Quality System Regulation’s (QSR’s) current good manufacturing practice (CGMP)...
Insights and Analysis
31 January 2024
In this Q4/23 issue of our Life Science and Health Care Law Update, our teams highlight key trends across life sciences regulatory, corporate, compliance, competition, and privacy...
